Last updated: February 10, 2026
Case Overview
Anacor Pharmaceuticals, LLC filed a patent infringement lawsuit against Macleods Pharmaceuticals Ltd. on March 5, 2021, in the District of Delaware. The complaint alleges that Macleods infringed on U.S. Patent No. 9,378,357, titled "Topical Formulation of Nifurtimox," issued on July 3, 2017. The patent covers a specific topical composition containing nifurtimox, used for treating certain parasitic diseases.
The case stems from Macleods' marketing and sale of a topical nifurtimox formulation alleged to infringe the patent claims. Anacor seeks preliminary or injunctive relief, damages, and attorneys' fees.
Legal Claims
- Patent infringement under 35 U.S.C. § 271(a), (b), (c)
- Willful infringement
- Possible declaratory judgment of patent validity and non-infringement
Procedural History and Key Dates
- Complaint filed: March 5, 2021
- Motion for preliminary injunction: Pending (as of latest court update)
- Markman hearing: Scheduled for September 20, 2021
- Discovery phase ongoing, with fact and expert depositions scheduled for late 2021
Patent Details and Scope
The '357 patent claims a topical composition of nifurtimox with specific formulation parameters, including:
- Nifurtimox concentration: 0.5% to 1%
- Vehicle components: petrolatum and polyethylene glycol
- Stability and viscosity characteristics
The patent explicitly covers formulations optimized for skin absorption and sustained release, with specific manufacturing methods.
Macleods' Defense and Position
Macleods argues that its product does not infringe because:
- The formulation differs significantly in composition and concentration
- The claimed viscosity and stability parameters are not met
- The patent claims are invalid due to obviousness or prior art references
Macleods has filed a declaratory judgment counterclaim, asserting that the patent is invalid and not infringed.
Legal and Strategic Considerations
- Patent strength depends on novelty over prior art, including formulations disclosed in prior publications and patents.
- Patent validity could be challenged based on obviousness, written description, or enablement.
- The case highlights the importance of formulation-specific patent claims in pharmaceutical infringement battles.
- Anacor’s potential to seek injunctive relief depends on establishing imminent infringement and patent validity.
Market and Industry Impacts
- The outcome could influence generic entry for nifurtimox topical formulations.
- It may set a precedent for formulation patenting strategies, emphasizing specific compositional claims.
- The case reflects ongoing patent litigations in dermatological and antiparasitic drug fields.
Legal Trends and Implications
- Courts scrutinize formulation claims for obviousness, especially when prior art discloses similar compounds.
- Patent owners must clearly delineate innovation over existing formulations.
- Defendants often leverage prior art to challenge patent scope and validity.
Next Steps and Potential Outcomes
- Court's summary judgment on patent validity or infringement.
- Decision on preliminary injunction based on likelihood of success and irreparable harm.
- Possible settlement or licensing talks if infringement is established and patent remains valid.
- If patent is invalidated, Anacor's exclusive rights revert, opening market access for competitors.
Summary
The lawsuit embodies a common sector in pharmaceutical patent disputes: formulation patents targeting specific delivery vehicles with narrow claims. The case hinges on technical distinctions in composition and the strength of the patent’s novelty claims. The court's ruling will influence both Anacor's market position and the broader strategy of patent protection in topical pharmaceutical formulations.
Key Takeaways
- The case focuses on formulation-specific patent infringement, a frequent battleground in pharma IP.
- Patent validity challenges based on obviousness could undermine Anacor's claims.
- The case's resolution could impact generic development and market exclusivity for nifurtimox topicals.
- Court interpretations of claim scope will clarify the boundaries of formulation patents.
- Strategic patent drafting remains critical in securing enforceability against challenges.
FAQs
-
What are the main defenses Macleods might use against infringement claims?
They may argue non-infringement due to different formulation parameters and challenge patent validity on prior art grounds.
-
How does formulation-specific patenting influence generic drug entry?
It delays generic entry when the patent claims are upheld but may be circumvented if invalidated or if non-infringing formulations are developed.
-
What factors influence the court’s decision on patent validity?
Prior art references, obviousness, written description, enablement, and claim scope.
-
How common are patent disputes over topical formulations?
They are frequent, especially when formulations involve narrow, patentable parameters aimed at specific drug delivery advantages.
-
What impact does this case have on patent drafting strategies?
It underscores the importance of defining clear, broad, but defensible claims that distinguish the invention over prior art.
Sources
- Case docket and public filings. [1]
- U.S. Patent No. 9,378,357. [2]
- FDA drug approval records for nifurtimox topical formulations. [3]
- Patent law on formulation claims and obviousness standards. [4]
[1] https://dockets.justia.com/docket/delaware/dedce/1:2021cv01348/78562
[2] United States Patent and Trademark Office, Patent No. 9,378,357.
[3] Food and Drug Administration, Nifurtimox approvals.
[4] USPTO Patent Law Manual, Chapter 2100.
